11/21
09:00 am
lumo
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
Neutral
Report
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
11/8
11:37 am
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.
Low
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock.
11/6
02:38 pm
lumo
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
Low
Report
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMO
10/30
04:05 pm
lumo
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024
Low
Report
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62n? Annual ESPE Meeting 2024
10/24
07:50 pm
lumo
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders
Neutral
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, ZUO, ARC on Behalf of Shareholders
10/24
03:27 pm
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock, down previously from $28.00.
Low
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.25 price target on the stock, down previously from $28.00.
10/24
07:49 am
lumo
DPV set to acquire Lumos Pharma for $38m [Yahoo! Finance]
Low
Report
DPV set to acquire Lumos Pharma for $38m [Yahoo! Finance]
10/23
03:51 pm
lumo
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
Low
Report
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc.
10/23
03:31 pm
lumo
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
Low
Report
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders
10/23
10:28 am
lumo
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
Low
Report
LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
10/23
08:59 am
lumo
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Low
Report
Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
10/23
08:25 am
lumo
Lumos inks take-private deal with Double Point Ventures [Seeking Alpha]
Low
Report
Lumos inks take-private deal with Double Point Ventures [Seeking Alpha]
10/23
08:00 am
lumo
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
Medium
Report
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
9/27
11:05 am
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Medium
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
9/27
07:36 am
lumo
Lumos Pharma, Inc. (NASDAQ: LUMO) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
Lumos Pharma, Inc. (NASDAQ: LUMO) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
9/25
04:05 pm
lumo
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Medium
Report
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
9/5
09:00 am
lumo
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
Low
Report
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024